Table: Taisho Pharmaceutical HD - 6-MTH group results
Oct 29 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2018 Sep 30, 2017 Mar 31, 2019
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 129.49 138.63 269.00
(-6.6 pct) (-1.7 pct) (-4.0 pct)
Operating 16.99 15.18 33.00
(+11.9 pct) (-8.9 pct) (-10.8 pct)
Recurring 22.71 17.85 39.50
(+27.2 pct) (-6.7 pct) (-6.3 pct)
Net 42.43 12.02 55.50
(+253.1 pct) (-11.0 pct) (+75.2 pct)
EPS 531.62 yen 150.38 yen 694.62 yen
EPS Diluted 531.14 yen 150.26 yen
Ann Div 110.00 yen 110.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 60.00 yen 60.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10